MedTrace Logo

Stage II/III Colorectal Cancer Recurrence

NCT06314958 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-07-04

No results posted yet for this study

Summary

This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

Conditions

  • Colorectal Cancer
  • Colorectal Adenocarcinoma
  • Colorectal Cancer Stage II
  • Colorectal Cancer Stage III
  • Colorectal Cancer Recurrent

Interventions

OTHER

CENSURE

A panel of CpG sites, whose methylation level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Ajay Goel, PhD · City of Hope Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2026-06-18
Completion
2026-06-18

Countries

  • United States
  • China
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06314958 on ClinicalTrials.gov